Slowing growth and sticky inflation: Is it time to reduce US equity exposure?

The pharma sector, often seen as defensive, could attract investment if global economic uncertainty rises. However, Indian pharma companies with significant US exposure might face headwinds from a slowing US economy and pricing pressures.

Consider defensive Indian pharma stocks with strong domestic focus or diversified global presence, while being cautious on those heavily reliant on US generics market.

For Indian markets, this story mainly matters for the Information Technology, Pharmaceuticals pocket. The current signal is mixed, so traders should watch whether the effect spreads across the sector or stays limited to a single name.

Watch whether the market validates this read through price action, volume, and breadth. If the headline matters, the signal should show up in execution, not just in commentary.

• •US inflation remains stubbornly high.
• •US growth is slowing.
• •Experts are debating whether investors should reconsider US equity exposure.
• •Geopolitical tensions and market dynamics are reshaping US investment strategies.
• •Risk flag: Continued US pricing pressure on generics